A clearer view on ovarian clear cell carcinoma. Issue 4 (4th July 2022)

• Record Type: Journal Article
• Authors: De Pauw, Aglaja; Naert, Eline; Van de Vijver, Koen; Philippe, Tummers; Vandecasteele, Katrien; Denys, Hannelore
• Is Part Of: Acta clinica belgica. Volume 77:Issue 4(2022)
• Page Start: 792
• Page End: 804
• Publication Date: 2022-07-04
• Subjects: Ovarian clear cell carcinoma -- Endometriosis -- Chemotherapy -- Radiotherapy -- Gynecological surgery; Clinical medicine -- Periodicals; Diagnosis, Laboratory -- Periodicals; 616.005
• DOI: 10.1080/17843286.2021.1964051
• Languages: English
• ISSNs: 1784-3286

Abstract

ABSTRACT: Introduction: Ovarian clear cell carcinoma (OCCC) is a less common subtype accounting for approximately 5% of all epithelial ovarian cancers (EOCs). Clinical experience and research findings confirm the remarkable differences in clinical behavior, molecular alterations and pathogenesis of OCCC. The diagnosis of OCCC is typically set at a younger age, and earlier stage and in a background of endometriosis. Results: Molecularly, OCCCs rarely harbor BRCA1/BRCA2 mutations and have fewer copy number variants (CNVs). The most common molecular changes occur in the SWI/SNF chromatin remodeling complex genes, the PI3K/AKT signaling pathway and the receptor tyrosine kinase (RTK)/Ras signaling pathway.Five-year disease-specific survival of patients with OCCC is worse compared to high grade serous carcinomas (HGSOC). The current treatment options for OCCC are based on studies that included patients with predominantly HGSOC and only a minor proportion of cancers with clear cell histology. In order to improve outcomes for patients with OCCC, research should be specific for this subtype. Discussion: As the available information about the specific characteristics of OCCC is increasing, especially at a molecular level, it should be possible to continuously improve the specific diagnostics and treatment. Since OCCC is so rare, it is essential to collect new evidence at an international level. To avoid extrapolation from EOC trials with possible erroneous conclusions, patients should always be encouraged to participate in specific histological trials and basket trials, while paying extra attention to OCCC-like subtypes.